# K192858: A1AT Genotyping Test

- Pathway: 510(k) (Special)
- Applicant: Progenika Biopharma S.A., A Grifols Company
- Decided: Nov 5, 2019 after 32 days
- Product code: PZH (Serpina1 Variant Detection System)
- Device class: 2
- Regulation: 21 CFR 866.5130
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 2 generations back to K063498 (2007). 2 ancestors in all.
1 later device descends from it; 1 cites it directly.
0 of 4 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K171868: A1AT Genotyping Test, Progenika Biopharma S.A., A Grifols Company (2017) Summary page 5.

## Most influential descendants
- K211115: A1AT Genotyping Test (2021), 0 descendants of its own

## Indications for use
The Progenika A1AT genotyping kit is a quantitative, polymerase chain reaction (PCR) and hybridization-based in vitro diagnostic test to be used with the Luminex 200 instrument (with xPONENT software) for the simultaneous detection and identification of 14 allelic variants and their associated alleles found in the Alpha-1 antitrypsin (A1AT) codifying gene SERPINA1. The test intended for use with genomic DNA extracted from human whole blood samples collected as dry blood spot (DBS) or in K2-EDTA or from human saliva samples collected as buccal swabs using ORAcollect Dx model OCD-100. The A1AT allelic variant genotypes and associated allele results, when used in conjunction with clinical findings and other laboratory tests, are intended as an aid in the diagnosis of individuals with A1AT deficiency (A1ATD). The kit is indicated for prescription use only.

Source page: https://510kreport.com/device/K192858
Methodology: https://510kreport.com/methodology